Publication
Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes.
Yue Lv, Qiang Yin, Wuheng Li, Leihong Deng, Jiasheng Liu, Haolong Lv, Peng Zhang, Yihang Qiu, Difeng Guo, Rui Tao, Xiuguo Gan, Fanghua Xu, Zan Liu, Yongquan Wang
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Bladder cancer (BLCA) is an aggressive malignancy characterized by metastasis and drug resistance, creating an urgent demand for novel therapeutic targets. The lysosomal protein LAMP2 acts as a key oncogenic driver in BLCA and modulates the degradation of STING. As reported in prior studies,…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available